RU2007102847A - Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev - Google Patents

Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev Download PDF

Info

Publication number
RU2007102847A
RU2007102847A RU2007102847/15A RU2007102847A RU2007102847A RU 2007102847 A RU2007102847 A RU 2007102847A RU 2007102847/15 A RU2007102847/15 A RU 2007102847/15A RU 2007102847 A RU2007102847 A RU 2007102847A RU 2007102847 A RU2007102847 A RU 2007102847A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
incontinence
ethyl
Prior art date
Application number
RU2007102847/15A
Other languages
English (en)
Other versions
RU2349323C2 (ru
Inventor
Бернадетт ХЬЮЗ (GB)
Бернадетт ХЬЮЗ
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0417777A external-priority patent/GB0417777D0/en
Application filed by Пфайзер Инк. (US), Пфайзер Инк. filed Critical Пфайзер Инк. (US)
Publication of RU2007102847A publication Critical patent/RU2007102847A/ru
Application granted granted Critical
Publication of RU2349323C2 publication Critical patent/RU2349323C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)

Claims (11)

1. Комбинация, состоящая из
(а) (S,S)-ребоксетина или его фармацевтически приемлемой соли или сольвата
и (б) ингибитора фосфодиэстеразы типа 5 (PDEV),
2. Комбинация по п.1, где ингибитор фосфодиэстеразы типа 5 (PDEV) выбран из:
5-[2-этокси-5-(4-метил-1-пиперазинилсульфонил)фенил]-1-метил-3-н-пропил-1,6-дигидро-7Н-пиразоло[4,3-d]пиримидин-7-она (силденафил) или его фармацевтически приемлемой соли или сольвата;
(6R,12аR)-2,3,6,7,12,12а-гексагидро-2-метил-6-(3,4-метилендиоксифенил)-пиразино[2',1':6,1]пиридо[3,4-b]индол-1,4-диона(тадалафил, IC-351, Cialis®) или его фармацевтически приемлемой соли или сольвата;
2-[2-этокси-5-(4-этил-пиперазин-1-ил-1-сульфонил)-фенил]-5-метил-7-пропил-3H-имидазо[5,1-f][1,2,4]триазин-4-она(варденафил) или его фармацевтически приемлемой соли или сольвата;
5-[2-этокси-5-(4-этилпиперазин-1-илсульфонил)пиридин-3-ил]-3-этил-2-[2-метоксиэтил]-2,6-дигидро-7H-пиразоло[4,3-d]1пиримидин-7-она или его фармацевтически приемлемой соли или сольвата;
5-(5-ацетил-2-бутокси-3-пиридинил)-3-этил-2-(1-этил-3-азетидинил)-2,6-дигидро-7H-пиразоло[4,3-d]пиримидин-7-она или его фармацевтически приемлемой соли или сольвата;
1-{6-этокси-5-[3-этил-6,7-дигидро-2-(2-метоксиэтил)-7-оксо-2H-пиразоло[4,3-d]пиримидин-5-ил]-3-пиридилсульфонил}-4-этилпиперазина или его фармацевтически приемлемой соли или сольвата;
N-[1-(2-этоксиэтил)-5-(N-этил-N-метиламино)-7-(4-метилпиридин-2-иламино)-1H-пиразоло[4,3-d]пиримидин-3-карбонил]метансульфонамида или его фармацевтически приемлемой соли или сольвата;
3-этил-5-[5-(4-этилпиперазин-1-илсульфонил)-2-н-пропоксифенил]-2-(пиридин-2-ил)метил-2,6-дигидро-7H-пиразоло[4,3-d]пиримидин-7-она или его фармацевтически приемлемой соли или сольвата и
{3-этил-5-[(R)-3-метил-пиперазин-1-ил]-1-[2-(2,2,2-трифторэтокси)-этил]-1H-пиразоло[4,3-d]1пиримидин-7-ил}-пиримидин-4-ил-амина или его фармацевтически приемлемой соли или сольвата.
3. Фармацевтическая композиция, состоящая из
(а) (S,S)-ребоксетина или его фармацевтически приемлемой соли или сольвата,
(б) ингибитора фосфодиэстеразы типа 5 (PDEV) и
(в) фармацевтически приемлемого эксципиента, разбавителя или носителя.
4. Комбинация по п.1 или 2 для применения в качестве лекарственного средства.
5. Применение комбинации по п.1 или 2 в изготовлении лекарственного средства для одновременного, последовательного или раздельного введения обоих агентов при лечении боли.
6. Способ лечения боли, включающий одновременное, последовательное или раздельное введение млекопитающему, нуждающемуся в таком лечении, эффективного количества комбинации по п.1 или 2.
7. Применение комбинации по п.1 или 2 в изготовлении лекарственного средства для одновременного, последовательного или раздельного введения обоих агентов при лечении недержания.
8. Применение по п.7, где недержание выбрано из недержания при напряжении, истинного недержания при напряжении, неудержания и смешанного недержания.
9. Способ лечения недержания, включающий одновременное, последовательное или раздельное введение млекопитающему, нуждающемуся в таком лечении, эффективного количества комбинации по п.1 или 2.
10. Способ по п.9, где недержание мочи выбрано из недержания при напряжении, истинного недержания при напряжении, неудержания и смешанного недержания.
11. Набор, по существу состоящий из
(а) (S,S)-ребоксетина или его фармацевтически приемлемой соли или сольвата,
(б) ингибитора фосфодиэстеразы типа 5 (PDEV) и
(в) средств для содержания указанных соединений.
RU2007102847/15A 2004-08-10 2005-07-29 Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev RU2349323C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0417777.0 2004-08-10
GB0417777A GB0417777D0 (en) 2004-08-10 2004-08-10 Pharmaceutical combination
US60630204P 2004-08-31 2004-08-31
US60/606,302 2004-08-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2008131792/15A Division RU2008131792A (ru) 2004-08-10 2008-08-04 Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev

Publications (2)

Publication Number Publication Date
RU2007102847A true RU2007102847A (ru) 2008-09-20
RU2349323C2 RU2349323C2 (ru) 2009-03-20

Family

ID=35044604

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007102847/15A RU2349323C2 (ru) 2004-08-10 2005-07-29 Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev
RU2008131792/15A RU2008131792A (ru) 2004-08-10 2008-08-04 Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2008131792/15A RU2008131792A (ru) 2004-08-10 2008-08-04 Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev

Country Status (12)

Country Link
US (1) US20090227562A1 (ru)
EP (1) EP1778241A1 (ru)
JP (1) JP2008509900A (ru)
KR (2) KR20070036171A (ru)
AU (1) AU2005270904A1 (ru)
BR (1) BRPI0514296A (ru)
CA (1) CA2575980A1 (ru)
IL (1) IL180557A0 (ru)
MX (1) MX2007000694A (ru)
NO (1) NO20066059L (ru)
RU (2) RU2349323C2 (ru)
WO (1) WO2006016262A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420881T1 (de) 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
EP1771452A4 (en) * 2004-07-27 2009-07-15 Biocryst Pharm Inc 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND 5'METHYL THIOADENOSINE / S-ADENOSYLHOMOCYSTEIN NUCLEOSIDASE HEMMER
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2008273867A (ja) * 2007-04-27 2008-11-13 Asahi Kasei Pharma Kk 経粘膜投与用製剤
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CA2687679A1 (en) * 2007-05-18 2008-11-27 Vivus, Inc. Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
US20090131442A1 (en) * 2007-11-16 2009-05-21 Joseph Bernstein Method of Treating Bone Pain Caused by Osteoarthritis
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
CN102018550B (zh) * 2010-12-01 2012-04-25 中国人民解放军第四军医大学 后纵韧带犁刀
EP3189835B1 (en) * 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
AU2013336293B2 (en) * 2012-10-23 2016-05-12 Pfizer Inc. Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy
WO2014130910A1 (en) * 2013-02-22 2014-08-28 Baylor College Of Medicine Treatment for substance use disorders and stress disorders
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
WO2022098180A1 (en) * 2020-11-05 2022-05-12 Neurorive Inc Combination therapy of donepezil and pde inhibitor for the treatment of alzheimer's disease or cognitive impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations

Also Published As

Publication number Publication date
CA2575980A1 (en) 2006-02-16
AU2005270904A1 (en) 2006-02-16
JP2008509900A (ja) 2008-04-03
BRPI0514296A (pt) 2008-06-17
IL180557A0 (en) 2008-03-20
KR20080064911A (ko) 2008-07-09
WO2006016262A1 (en) 2006-02-16
WO2006016262A8 (en) 2006-06-29
US20090227562A1 (en) 2009-09-10
NO20066059L (no) 2007-01-29
KR20070036171A (ko) 2007-04-02
MX2007000694A (es) 2007-03-12
EP1778241A1 (en) 2007-05-02
RU2349323C2 (ru) 2009-03-20
RU2008131792A (ru) 2010-02-10

Similar Documents

Publication Publication Date Title
RU2007102847A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
KR100363714B1 (ko) 니트레이트-유발된 내성을 치료하기 위한 약학 조성물
ZA201808534B (en) Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
RS52730B (sr) Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
JP2013526598A5 (ru)
BG106383A (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
HRP20070534T3 (en) Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
JP2016538316A5 (ru)
JP2007526285A5 (ru)
RU2017106742A (ru) Комбинированная терапия для лечения парамиксовируса
US11166956B2 (en) Combinations of PDE1 inhibitors and NEP inhibitors
CZ153795A3 (en) Novel antagonists of corticotropin releasing factor
KR880007535A (ko) 설포닐우레아 화합물
RU2006136362A (ru) Способ лечения инфаркта миокарда
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
JP2006528229A5 (ru)
US20230406860A1 (en) Heterocyclic spiro compounds and methods of use
AR044648A1 (es) Combinaciones terapeuticas
CA2529007A1 (en) Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
CA2500225A1 (en) Pyrazole compounds
RU2004136276A (ru) Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11
ZA200208776B (en) Daily treatment for erectile dysfunction using a PDE5 innhibitor.
ATE320247T1 (de) Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion
AR040090A1 (es) Nueva combinacion

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090730